Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment

Transfusion

Volumn 56, Issue 12, 2016, Pages 2948-2952

  Keil, Shawn D ^a   Bowen, Richard ^b   Marschner, Susanne ^a  

^a Terumo BCT   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN;

ARTICLE; HUMAN; IN VITRO STUDY; LIMIT OF DETECTION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PHOTOCHEMISTRY; PLASMA; ULTRAVIOLET RADIATION; VERO CELL LINE; VIRAL PLAQUE ASSAY; VIRUS INACTIVATION; VIRUS LOAD; VIRUS STRAIN; ADVERSE EFFECTS; ANIMAL; BLOOD SAFETY; BLOODBORNE BACTERIUM; CHLOROCEBUS AETHIOPS; CORONAVIRUS INFECTIONS; DRUG EFFECTS; PATHOGENICITY; RADIATION RESPONSE; TRANSMISSION; VIROLOGY;

ANIMALS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; CERCOPITHECUS AETHIOPS; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PLASMA; RIBOFLAVIN; ULTRAVIOLET RAYS; VERO CELLS; VIRAL LOAD; VIRUS INACTIVATION;

EID: 84997403740     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13860     Document Type: Article

References (22)

1. Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014;9:30–6.
2. Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med 2015;13:210.
3. Kingdom of Saudi Arabia, Ministry of Health. MERS-CoV Statistics. [cited 2015 Sep 27] Available from: http://www.moh.gov.sa/en/CCC/PressReleases/Pages/default.aspx.
4. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV); MERS-CoV in Republic of Korea at a glance. World Health Organization. [cited 2015 Sep 28] Available from: http://www.wpro.who.int/outbreaks_emergencies/wpro_coronavirus/en/.
5. Rha B, Rudd J, Feikin D, et al. Centers for Disease Control and Prevention. Update on the epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, and guidance for the public, clinicians, and public health authorities—January 2015. MMWR Morb Mortal Wkly Rep 2015;64:61–2.
6. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–76.
7. Berger A, Drosten Ch, Doerr HW, et al. Severe acute respiratory syndrome (SARS)—paradigm of an emerging viral infection. J Clin Virol 2004;29:13–22.
8. Middle East respiratory syndrome coronavirus. American Association of Blood Banks. [cited 2015 Sep 27] Available from: http://www.aabb.org/tm/eid/Documents/middle-east-respiratory-syndrome-coronavirus.pdf.
9. Keil SD, Bengrine A, Bowen R, et al. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 2015;55:1736–44.
10. Keil SD, Kiser P, Sullivan JJ, et al. Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013;53:2278–86.
11. Keil SD, Hovenga N, Gilmour D, et al. Treatment of platelet products with riboflavin and UV light: effectiveness against high titer bacterial contamination. J Vis Exp 2015;102:e52820.
12. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877–85.
13. Balint B, Jovicic-Gojkov D, Todorovic-Balint M, et al. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment—a comparative study. Transfus Apher Sci 2013;49:434–9.
14. Hornsey VS, Drummond O, Morrison A, et al. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009;49:2167–72.
15. Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010;50:926–31.
16. Adney DR, van Doremalen N, Brown VR, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis 2014;20:1999–2005.
17. European Directorate for the Quality of Medicines and Healthcare. Guide to the preparation, use, and quality assurance of blood components. 17th ed. Strasbourg (France): Council of Europe; 2013.
18. Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 2016;62:477–83.
19. Kaiser-Guignard J, Canellini G, Lion N, et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014;28:235–41.
20. Centers for Disease Control and Prevention. HIV transmission through transfusion—Missouri and Colorado, 2008. MMWR Morb Mortal Wkly 2010;59:1335–9.
21. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev 2012;26:164–80.
22. Woolhouse ME, Haydon DT, Antia R. Emerging pathogens: the epidemiology and evolution of species jumps. Trends Ecol Evol 2005;20:238–44.